Abstracts tagged "Cryogloblulinemic Vasculitis"

Abstract Number: 0777 • ACR Convergence 2024
Rheumatoid Factor B Cell Clones Proliferate Predominantly as Atypical Memory B Cells in Reactive Cervical Lymph Node Follicles Compared to Extrafollicular Sites in Affected Salivary Glands of SjS Patients
Theodoros Ioannis Papadimitriou¹, Jing Jing Wang², Xuehui He³, Sidney van der Zade⁴, Massis Krekorian⁵, Prashant Singh⁶, Erik Dik⁵, Ger Pruijn⁵, Tom Gordon², Hans Koenen⁷, Martijn Huijnen⁸ and Rogier Thurlings¹, ¹Radboudumc, Department of Rheumatology, Nijmegen, Gelderland, Netherlands, ²Flinders University, Adeleide, Australia, ³Radboudumc, Nijmegen, Netherlands, ⁴Radboudumc, Amsterdam, Netherlands, ⁵Radboudumc, Nijmegen, Gelderland, Netherlands, ⁶Radboudumc, Department of Medical BioSciences, Nijmegen, Netherlands, ⁷Radboudumc, Department of Medical Immunology, Nijmegen, Gelderland, Netherlands, ⁸Radboudumc, Department of Medical BioSciences, Nijmegen, Gelderland, Netherlands
Background/Purpose: Sjögren’s syndrome (SjS) is a chronic inflammatory disorder, characterized by formation of autoantibodies. Over time rheumatoid factor (RF) clones can give rise to cryoglobulinemic…
Abstract Number: 2514 • ACR Convergence 2024
The Pattern of Renal Involvement in Relapsing Cryoglobulinemic Vasculitis After Successful Sustained Viral Response by Direct-Acting Antiviral Treatments
Mohamed Tharwat Hegazy¹, Ahmed Fayed¹ and Gaafar Ragab², ¹Faculty of Medicine, Cairo University, Cairo, Egypt, ²Cairo University, Egypt, Cairo, Egypt
Background/Purpose: Interferon-free Direct Acting Antiviral (DAA) treatments proved to be effective for the treatment of HCV-induced Cryoglobulinemic Vasculitis (HCV-Cryovas). Some reports showed relapses of HCV-Cryovas…
Abstract Number: 0691 • ACR Convergence 2023
Recognizing the New Disorder “Idiopathic Hypocryoglobulinaemia” in Patients with Previously Unidentified Clinical Conditions
Dario Roccatello¹, Savino Sciascia², carla naretto³, ANTONELLA BARRECA⁴, MASSIMO RADIN⁵, IRENE CECCHI⁵, ALICE BARINOTTI⁵, ELENA RUBINI⁵, SILVIA GRAZIETTA FODDAI⁵, laura solfietti³, laura battaglia³, lucia vizziello³, ROBERTA FENOGLIO³ and DANIELA ROSSI³, ¹University of Torino, Torino, Italy, ²University of Turin, Torino, Italy, ³University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, Turin, Italy, ⁴Pathology Unit, Città della Salute e della Scienza, Turin, Italy, ⁵University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
Background/Purpose: A considerable number of patients with high clinical suspicion for cryoglobulinaemic vasculitis either show negative results for the detection of cryoglobulins or show only…
Abstract Number: 1281 • ACR Convergence 2022
Less Than Half of Cryoglobulin Tests Ordered at a Tertiary Hospital Network Are Successfully Completed: An Opportunity for Improvement
Joo Young (Esther) Lee¹, Alexis Baass², Sasha Bernatsky³, Evelyne Vinet² and Arielle Mendel², ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Cryoglobulin detection is essential for the diagnosis of cryoglobulinemic vasculitis, a condition leading to high healthcare use, organ damage, and even death. Successful cryoglobulin…
Abstract Number: 1574 • ACR Convergence 2022
Vasculitides as Medication-Associated Adverse Events Based on a National Database Reporting System
Alicia Rodriguez-Pla, Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Vasculitides have been reported as adverse events (AEs) related to a wide variety of medications. We aimed to analyze the vasculitides reported to a…
Abstract Number: 0414 • ACR Convergence 2020
Clinical Characteristics of an Internet-Based Cohort of Participants with a Self-Reported Diagnosis of Cryoglobulinemic Vasculitis or IgA Vasculitis
Jason Springer¹, Tanaz Kermani², Dianne Shaw³, Kalen Young⁴, Cristina Burroughs⁵ and Peter Merkel⁶, ¹University of Kansas Medical Center, Overland Park, KS, ²David Geffen School of Medicine / University of California, Los Angeles, CA, ³Vasculitis Foundation, North Carolina, ⁴Vasculitis Foundation, Kansas City, ⁵University of South Florida, Tampa, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cyroglobulinemic vasculitis (CV) and IgA vasculitis are forms of small-vessel vasculitis characterized by immune complex deposition. The purpose of this study was to a)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].